EASL Press Conference 2019 Upload video: No flash player has been set up. Please select a player to play Flash videos.
07Mar, 19MYR Pharmaceuticals Announces Grant of Promising Innovative Medicine (PIM) Designation by British MHRA for Bulevirtide (Myrcludex), the First-in-Class Entry Inhibitor for Treatment of Chronic Hepatitis D InfectionsMYR Pharmaceuticals announced today that the British Medicines and Healthcare products Regulatory Agency (MHRA) has...
04Apr, 19MYR Pharmaceuticals Announces Presentation of Final Results of the MYR203 Study of bulevirtide (Myrcludex) at the International Liver Congress (ILC) 2019 in Vienna.MYR Pharmaceuticals today announced that the final results of the MYR203 study of bulevirtide (Myrcludex), MYR´s...
23Oct, 18MYR Pharma Announces Grant of Breakthrough Therapy Designation by US FDA for Myrcludex, the First-in-Class Entry Inhibitor for Treatment of chronic Hepatitis B and D InfectionsMYR Pharma today announced that US Food and Drug Administration (FDA) has granted the Breakthrough Therapy designation...
30Sep, 14Press Release, Moscow, October, 2014Maxwell Biotech Portfolio Company Hepatera Announces Proof-of-Concept Clinical Results with Myrcludex B, a Novel Entry...
13Apr, 19ILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with PEG-IFN-a in Phase 2b study involving individuals with chronic hepatitis B/D virus coinfection, producing high rates of viral suppression bILC 2019: First-in-class entry inhibitor bulevirtide (Myrcludex B) effective and well tolerated in combination with...
